Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HAE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHaemonetics director Charles Dockendorff to step down after 12-year tenure
Filed May 1, 2026 · Period ending April 27, 2026 · ~1 min read
Key Changes
-
low
Board member Charles J. Dockendorff will not seek re-election at the 2026 Annual Meeting, ending a 12-year tenure that began in 2014. He currently serves on both the Audit and Governance committees.
Item 5.02 verify on EDGAR → -
low
Dockendorff will continue serving as director and in his committee roles until the Annual Meeting. The company explicitly stated his departure is not due to any disagreement with management or the board.
8-K: Director Departure view on EDGAR →
Summary
Haemonetics disclosed that long-serving director Charles J. Dockendorff will not stand for re-election at the company's 2026 Annual Meeting of Shareholders. Dockendorff has been on the board since 2014 and currently serves on two key committees: Audit and Governance & Compliance.
The company emphasized that his decision is not the result of any disagreement, suggesting this is a routine board transition rather than a contentious departure. For retail investors, this is a low-impact procedural disclosure. Board turnover after 12 years of service is normal corporate governance, and the explicit statement about no disagreements reduces concerns about underlying issues.
The timing allows for an orderly transition, as Dockendorff will remain in his roles until the Annual Meeting. Investors should watch for the company's proxy statement, which will reveal Dockendorff's replacement nominee and provide insight into the board's composition and expertise going forward.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”). Mr. Dockendorff has served as a member of the Board of Directors (the “Board”) of the Company since 2014 and currently serves as a member of the Audit Committee and the Governance and Compliance Committee. Mr. Dockendorff will continue to serve as a director and in his committee roles until the 2026 Annual Meeting. Mr. Dockendorff’s decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with the Company.
Charles J. Dockendorff, a board member since 2014 serving on the Audit and Governance committees, notified the company he will not seek re-election at the upcoming 2026 Annual Meeting. He will remain in his current roles until that meeting. The company explicitly states his departure is not due to any disagreement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify